Lixte Biotechnology Hldgs Inc Stock Price, News & Analysis

Lixte Biotechnology (NASDAQ:LIXT) has successfully closed a $1.5 million registered direct offering with accredited investors. The offering comprised 974,026 shares of Common Stock (or Pre-Funded Warrants) at $1.54 per share ($1.53999 for Pre-Funded Warrants with a $0.00001 exercise price).

The transaction, which closed on July 8, 2025, was conducted under an effective shelf registration statement, with Spartan Capital Securities acting as the exclusive placement agent. The company plans to utilize the net proceeds for general corporate purposes and working capital, combining them with existing cash reserves.

Lixte Biotechnology (NASDAQ:LIXT) has closed a $5.0 million private placement with accredited investors. The offering includes 2,382,084 shares of Common Stock (or Pre-funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants.

The Common Warrants have an initial exercise price of $1.00 per share and a 60-month expiration period after the resale registration effectiveness. Of the total proceeds, $4.0 million was paid at closing, with the remaining $1.0 million to be paid upon resale registration statement effectiveness. The company plans to use the funds for general corporate purposes and working capital.

Lixte Biotechnology Holdings (NASDAQ: LIXT), a clinical stage pharmaceutical company, has announced a $5.0 million private placement of securities priced at market. The offering includes 2,382,084 shares of Common Stock (or Pre-funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants.

The transaction structure includes $4.0 million payable at closing and $1.0 million upon effectiveness of the resale registration statement. The Common Warrants have an initial exercise price of $1.00 per share and a 60-month term. Spartan Capital Securities, LLC is serving as the exclusive placement agent.

The company plans to use the net proceeds for general corporate purposes and working capital. The closing is expected around July 2, 2025, subject to customary conditions.

LIXTE Biotechnology (Nasdaq: LIXT) has announced a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test if their compound LB-100 can eliminate pre-cancerous 'initiated' cells that carry mutations found in cancer cells.

The study builds upon LIXTE's ongoing clinical trials in ovarian and colorectal cancer. Recent data from their NKI collaboration shows LB-100 activates oncogenic signaling, which is detrimental to cancer cells. The new animal model study will specifically investigate if cells harboring mutant RAS oncogene can be eliminated with LB-100.

If successful, LB-100 could potentially reduce cancer risk in aging populations by eliminating initiated cells. The research will be led by Dr. René Bernards, Senior Staff Scientist at NKI and LIXTE board member. Phase 1 trials have already demonstrated LB-100's patient tolerance with minimal toxicity.

LIXTE Biotechnology (LIXT) has announced significant progress in its cancer treatment development programs. The company has initiated two new clinical trials for its lead compound LB-100: a Phase 1b/2 trial combining LB-100 with GSK's dostarlimab-gxly for ovarian clear cell carcinoma, and a trial with the Netherlands Cancer Institute and Roche for unresponsive metastatic colorectal cancer.

Key developments include successful patient dosing in both trials, receipt of a USPTO Notice of Allowance for combining LB-100 with cancer immunotherapies, and completion of a $1,050,000 registered direct offering. Two breakthrough studies were published: one in Cancer Discovery showing LB-100's ability to force cancer cells to relinquish malignant properties, and another in EMBO demonstrating how LB-100 makes cancer cells more vulnerable to immunotherapy.

LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced new pre-clinical data published in BioXriv and International Journal of Pharmaceutics regarding their lead clinical compound LB-100. The research reveals how LB-100 converts into its active form, endothall, a protein phosphatase inhibitor effective in cancer treatment with immunotherapy.

Scientists at the Netherlands Cancer Institute discovered an enzyme that mediates LB-100's conversion into endothall, potentially serving as a biomarker to identify patients most likely to respond to treatment. Additionally, research by BioPharmaWorks showed that while LB-100 can spontaneously convert to endothall through hydrolysis under physiological conditions, this process is slow, with the newly discovered enzymatic conversion accelerating the activation inside cells.

The company is currently conducting clinical trials of LB-100 for ovarian cancer and colorectal cancer treatment. These findings will help optimize patient selection for future clinical trials.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has expanded its clinical trial for ovarian clear cell cancer by adding the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as a second site. The trial combines LIXTE's proprietary compound LB-100 with GSK's immunotherapy Dostarlimab.

Dr. Emily M. Hinchcliff will lead the trial at Lurie Cancer Center, where patient recruitment is underway and the first patient has already been dosed. This expansion follows the trial's initial launch in January 2024 at The University of Texas MD Anderson Cancer Center under lead investigator Dr. Amir Jazaeri.

The clinical trial aims to determine if adding LB-100 to Dostarlimab enhances immunotherapy effectiveness in treating ovarian clear cell carcinoma, which represents a disease with high unmet medical needs.

LIXTE Biotechnology (Nasdaq: LIXT) has completed its previously announced registered direct offering, raising $1.05 million through the sale of 434,784 common shares at $2.415 per share. The company also issued unregistered warrants in a concurrent private placement to purchase up to 434,784 shares at an exercise price of $2.29, valid for five years.

H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds, after deducting placement agent fees and offering expenses, will be used for working capital and general corporate purposes. The common shares were offered through a shelf registration statement, while the warrants were issued through a private placement under Section 4(a)(2) of the Securities Act.

LIXTE Biotechnology (Nasdaq: LIXT) has announced a $1.05 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 434,784 shares of common stock at $2.415 per share, along with unregistered warrants in a concurrent private placement. The warrants, exercisable for five years, will allow purchase of up to 434,784 additional shares at $2.29 per share.

The offering, expected to close around February 12, 2025, is being exclusively placed by H.C. Wainwright & Co. LIXTE plans to use the net proceeds for working capital and general corporate purposes. The common stock offering is made through a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.